AIM: Lymphatic vessels are of special importance for tissue homeostasis, and increases of their density may foster tissue regeneration. Exercise could be a relevant tool to increase lymphatic vessel density (LVD); however, a significant lack of knowledge remains to understand lymphangiogenesis in skeletal muscles upon training. Interestingly, training-induced lymphangiogenesis has never been studied in the heart. We studied lymphangiogenesis and LVD upon chronic concentric and chronic @entity2472 in both @entity35 skeletal (Mm. Edl and @entity4625 ) and cardiac muscles. METHODS/RESULTS: We found that LVD decreased in both skeletal muscles specifically upon eccentric training, while this contraction increased LVD in cardiac tissue. These observations were supported by opposing local remodelling of lymphatic vessel-specific extracellular matrix components in skeletal and cardiac muscles and protein levels of lymphatic markers ( @entity36960 , @entity31192 , @entity18447 /D). Confocal microscopy further revealed transformations of lymphatic vessels into vessels expressing both blood ( @entity3895 -1) and lymphatic (Vegfr-3) markers upon eccentric training specifically in skeletal muscles. In addition and phenotype supportive, we found increased @entity32 ( @entity14185 / @entity12149 , @entity3426 , Ifn-y, @entity1505 and MPO(+) cells) in eccentrically stressed skeletal, but decreased levels in cardiac muscles. CONCLUSION: Our data provide novel mechanistic insights into lymphangiogenic processes in skeletal and cardiac muscles upon chronic muscle contraction modes and demonstrate that both tissues adapt in opposing manners specifically to eccentric training. These data are highly relevant for clinical applications, because eccentric training serves as a sufficient strategy to increase LVD and to decrease @entity32 in cardiac tissue, for example in order to reduce tissue abortion in transplantation settings.

The muscle contraction mode determines lymphangiogenesis differentially in XXXX skeletal and cardiac muscles by modifying local lymphatic extracellular matrix microenvironments.

@entity4625 :: ('MESH:D019904', 'Chemical') :: ['Sol'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity12149 :: ('25716(Tax:10116)', 'Gene') :: ['p65'] @entity1505 :: ('24835(Tax:10116)', 'Gene') :: ['Tnf-a'] @entity14185 :: ('309165(Tax:10116)', 'Gene') :: ['NF-kB'] @entity3426 :: ('24494(Tax:10116)', 'Gene') :: ['Il-1b'] @entity31192 :: ('54320(Tax:10116)', 'Gene') :: ['Pdpn'] @entity35 :: ('10116', 'Species') :: ['rat'] @entity18447 :: ('114111(Tax:10116)', 'Gene') :: ['Vegf-C'] @entity3895 :: ('10537', 'Species') :: ['Cav'] @entity36960 :: ('293186(Tax:10116)', 'Gene') :: ['Lyve-1'] @entity2472 :: ('MESH:C536214', 'Disease') :: ['eccentric muscle contractions']
@entity35 :: (10116,Species) :: ['rat']
